Evidence-Based Reviews

Using psychotropics safely in patients with HIV/AIDS: Watch for drug-drug interactions with antiretrovirals

Current Psychiatry. 2004 August;3(8):44-58

References

1. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. Am J Psychiatry. 2000 157 11(suppl). Also available at: www.psych.org/psych_pract/treatg/pg/hivaids_revisebook_index.cfm

2. Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention. HIV AIDS Surveill Rep December 2001. Available at: http://www.cdc.gov/hiv/stats/hasr1302.htm

3. Centers for Disease Control and Prevention. HIV AIDS Surveill Rep 2002;14:148. Also available at: http://www.cdc.gov/hiv/stats/hasr1402/2002SurveillanceReport.pdf

4. Risk reduction: sex without condoms. HIV Counselor Perspectives [newsletter] 2001;10(2, March).

5. Cournos F, McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: a critical review. Clin Psychol Rev 1997;17:259-69.

6. Steele FR. A moving target: CDC still trying to estimate HIV-1 prevalence. J NIH Res 1994;6:25-6.

7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.

8. Grant I, Atkinson JH, Jr. Neuropsychiatric aspects of HIV infection and AIDS. In: Sadock BJ, Sadock VA (eds). Kaplan and Sadock’s comprehensive textbook of psychiatry. Philadelphia: Lippincott Williams & Wilkins, 1999;308-36.

9. Ayuso JL. Use of psychotropic drugs in patients with HIV infection. Drugs 1994;47:599-610.

10. Mirken B. Danger: possibly fatal interactions between ritonavir and “ecstasy,” some other psychoactive drugs. AIDS Treat News 1997;Feb 21(No 265):5.-

11. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351(9106):871-5.

12. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19):1-39.

13. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16(6):1091-9.

14. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a working group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-85.

15. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995 Mar 1;8(3):273-8.

16. Silberstein CH, McKegney FP, O'Dowd MA, et al. A prospective longitudinal study of neuropsychological and psychosocial factors in asymptomatic individuals at risk for HTLV-III/LAV infection in a methadone program: preliminary findings. Int J Neurosci 1987;32(3-4):669-76.

17. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-6.

18. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 1999;13(13):1677-85.

19. Perry SW. Organic mental disorders caused by HIV: update on early diagnosis and treatment. Am J Psychiatry 1990;147(6):696-710.

20. Wilt SG, Milward E, Zhou JM, et al. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 1995;37(3):381-94.

21. Boven LA, Gomes L, Hery C, et al. Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J Immunol 1999;162(7):4319-27.

22. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Nov. 9, 2001;50(RR19):1-58.

23. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR July 18, 2003;52(RR12):1-24. Also available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5212a1.htm

24. Food and Drug Administration. Home Access HIV-1 Test System: Summary of safety and effectiveness. Available at: http://www.fda.gov/cber/PMAsumm/P950002S.pdf

25. Perry SW, Jacobsberg LB, Fishman B. Psychological responses to serological testing for HIV. AIDS 1990;4(2):145-52.

26. Opravil M, Ledergerber B, Furrer H. et al and the Swiss HIV Cohort Study Clinical benefit of early initiation of HAART in patients with asymptomatic HIV and CD4 counts >350/mm 3 . Abstract LB-6. Chicago, IL: 8th Conference on Retroviruses and Opportunistic Infections, 2001.

27. Marzuk P, Tierney H, Tardiff K, et al. Increased risk of suicide in persons with AIDS. JAMA 1988;259:1333-7.

28. Marzuk PM, Tardiff K, Leon AC, et al. HIV seroprevalence among suicide victims in New York City, 1991-93. Am J Psychiatry 1997;154(6):1720-5.